[an error occurred while processing this directive]

Research and Application Progress of Long acting Erythropoietin

  • LIU Ai-Chun ,
  • WEI Tao
Expand
  • Department of Nephrology, Peking University People’s Hospital, Beijing 100044, China

Received date: 2023-01-04

  Revised date: 2023-01-08

  Online published: 2023-03-03

Abstract

China has a large number of patients with renal anemia and tumor anemia after radiotherapy and chemotherapy. Long acting erythropoietin (EPO) has the advantages of long half-life and high biological activity. It can reduce the frequency and dose of administration, improve patient compliance and improve the effect of anemia treatment. This paper summarizes the design scheme, advantages and application prospects of long-acting EPO in order to provide a theoretical basis for promoting the wide application of long-acting EPO in China.

Cite this article

LIU Ai-Chun , WEI Tao . Research and Application Progress of Long acting Erythropoietin[J]. Chinese Journal of Blood Purification, 2023 , 22(03) : 161 -163 . DOI: 10.3969/j.issn.1671-4091.2023.03.001

Outlines

/

[an error occurred while processing this directive]